Tislelizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tislelizumab
Accession Number
DB14922
Type
Biotech
Groups
Investigational
Description

Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Synonyms
Not Available
External IDs
BGB-A317
Categories
Not Available
UNII
0KVO411B3N
CAS number
1858168-59-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Tislelizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCancer, Advanced1
1Not Yet RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
1RecruitingTreatmentLeukemias / Malignant Lymphomas1
1RecruitingTreatmentTumors, Solid1
1, 2Not Yet RecruitingTreatmentCarcinoma, Adenoid Cystic / Colorectal Cancers1
1, 2RecruitingTreatmentAdvanced Solid Tumors1
1, 2RecruitingTreatmentGastric/Gastroesophageal Junction Cancer / Hepatocellular,Carcinoma1
1, 2RecruitingTreatmentLocally Advanced or Metastatic Solid Tumors1
2Active Not RecruitingTreatmentClassical Hodgkin Lymphoma1
2Active Not RecruitingTreatmentEsophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma / Esophageal, Gastric, or Gastroesophageal Junction Carcinoma1
2Active Not RecruitingTreatmentHepatocellular Carcinoma (HCC)1
2Active Not RecruitingTreatmentLocally Advanced or Metastatic Urothelial Bladder Cancer1
2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / ALK-negative Anaplastic Large Cell Lymphoma / ALK-Positive Anaplastic Large Cell Lymphoma / Anaplastic Large Cell Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / Cutaneous T-Cell Lymphoma (CTCL) / Extranodal NK T Cell Lymphoma / Extranodal NK T Cell Lymphoma, Nasal / Extranodal NK/T-cell Lymphoma / Extranodal NK/T-cell Lymphoma, Nasal Type / Peripheral T Cell Lymphoma (PTCL) / Peripheral T-cell Lymphoma NOS / Peripheral T-Cell Lymphoma Refractory / Peripheral T-Cell Lymphoma, Not Otherwise Specified / PTCL / Recurrent Angioimmunoblastic T-cell Lymphoma / Refractory Angioimmunoblastic T-cell Lymphoma / Relapsed or Refractory Mature T- and Natural Killer (NK)-Cell Neoplasms1
2RecruitingTreatmentLocally Advanced Lung Cancer; Metastatic Lung Cancer / Locally Advanced or Metastatic Lung Cancer1
2RecruitingTreatmentMSI-H/dMMR Solid Tumors1
3RecruitingTreatmentEsophageal Squamous Cell Carcinoma (ESCC)1
3RecruitingTreatmentHepatocellular Carcinoma (HCC)1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:35 / Updated on May 21, 2019 12:31